Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX 株式レポート

時価総額:US$5.2b

Crinetics Pharmaceuticals 過去の業績

過去 基準チェック /06

Crinetics Pharmaceuticalsの収益は年間平均-33.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19.3% 28%割合で 増加しています。

主要情報

-33.6%

収益成長率

-12.8%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率28.0%
株主資本利益率-33.4%
ネット・マージン-26,747.8%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

収支内訳

Crinetics Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:CRNX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 241-27889169
30 Jun 241-25978169
31 Mar 242-23567169
31 Dec 234-21558169
30 Sep 235-19952130
30 Jun 235-18449130
31 Mar 234-17546130
31 Dec 225-16442130
30 Sep 225-150380
30 Jun 225-136330
31 Mar 224-119280
31 Dec 211-1082584
30 Sep 210-98220
30 Jun 210-89210
31 Mar 210-79190
31 Dec 200-74180
30 Sep 200-67160
30 Jun 201-63160
31 Mar 201-59140
31 Dec 191-50140
30 Sep 192-44130
30 Jun 192-38110
31 Mar 192-3190
31 Dec 182-2770
30 Sep 182-2150
30 Jun 182-1630
31 Mar 182-1230
31 Dec 172-920
31 Dec 161-620

質の高い収益: CRNXは現在利益が出ていません。

利益率の向上: CRNXは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: CRNXは利益が出ておらず、過去 5 年間で損失は年間33.6%の割合で増加しています。

成長の加速: CRNXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CRNXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: CRNXは現在利益が出ていないため、自己資本利益率 ( -33.36% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘